Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by BearDownAZon Jun 14, 2017 2:06pm
142 Views
Post# 26362471

RE:RE:RE:biOasis CEO Dr. Mark Day Releases Details of Corporate Plans

RE:RE:RE:biOasis CEO Dr. Mark Day Releases Details of Corporate PlansJD, with all due respect your argument is bogus. RH stated a year ago in email communication to me that "As for our oncology program we are in the process of preparing for a phase zero study, but the timing for that is predicated on material prep and patient availability." Furthermore, the MD&A from Jan 2017 states "Extensive protocols have been designed and approved and both Dr. Scarpa and the Phase Zero team in Australia are ready to begin these studies." The clear expectation is that the material should have been ready by now to start the studies, not wait up to another year for material prep. There is no sugar coating this JD. 

JD wrote: "With respect to manufacturing fusion proteins, over the last year I've told everybody who would listen that the first fusion protein would take 9 months to a year to manufacture....If you're defining Phase 0 as a project then the manufacture of the fusion proteins forms one of the first and most time consuming parts of the critical path to completion of the project. Many other elements of the project can be done concurrently with critical path elements."
Bullboard Posts